{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T11:04:04Z","timestamp":1777460644969,"version":"3.51.4"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2019,12,2]],"date-time":"2019-12-02T00:00:00Z","timestamp":1575244800000},"content-version":"vor","delay-in-days":1,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Grants-in-Aid from the Ministry of Education, Culture, Sports, Science and Technology of Japan for Scientific Research","award":["26293196"],"award-info":[{"award-number":["26293196"]}]},{"name":"Grants-in-Aid from the Ministry of Education, Culture, Sports, Science and Technology of Japan for Scientific Research","award":["26461216"],"award-info":[{"award-number":["26461216"]}]},{"name":"Grants-in-Aid from the Ministry of Education, Culture, Sports, Science and Technology of Japan for Young Scientists","award":["25870245"],"award-info":[{"award-number":["25870245"]}]},{"name":"Grants-in-Aid for the Practical Research Project for Renal Diseases from the Japan Agency for Medical Research and Development","award":["18ek0310007h0003"],"award-info":[{"award-number":["18ek0310007h0003"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2019,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n<jats:title>Background<\/jats:title>\n<jats:p>Cisplatin is a potent chemotherapeutic agent used to treat a variety of solid tumors. One of the major side effects of cisplatin is dose-limiting nephrotoxicity. We recently demonstrated that the renal uptake of cisplatin and resultant cisplatin-induced nephrotoxicity are mediated in part by megalin, an endocytic receptor in proximal tubule epithelial cells (PTECs). We also developed sandwich enzyme-linked immunosorbent assays to measure the megalin ectodomain (A-megalin) and full-length megalin (C-megalin) in urine using monoclonal antibodies against the amino- and carboxyl-termini of megalin, respectively. The present study examined the correlation of urinary megalin level with cisplatin-induced nephrotoxicity and its utility as a biomarker in patients with thoracic cancer.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Methods<\/jats:title>\n<jats:p>This prospective observational study involved 45 chemotherapy-na\u00efve patients scheduled to receive chemotherapy with \u226560\u2009mg\/m<jats:sup>2<\/jats:sup> cisplatin for histologically diagnosed small cell lung cancer, non-small cell lung cancer, or malignant pleural mesothelioma. Before and after the first course of chemotherapy, we measured urinary A- and C-megalin and other markers of PTEC injury, such as <jats:italic>N<\/jats:italic>-acetyl-\u03b2-D-glucosaminidase, \u03b1<jats:sub>1<\/jats:sub>-microglobulin, \u03b2<jats:sub>2<\/jats:sub>-microglobulin, neutrophil gelatinase-associated lipocalin, and liver-type fatty acid-binding protein, and compared the values with the change in the estimated glomerular filtration rate (eGFR) and clinical risk factors for renal impairment.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Results<\/jats:title>\n<jats:p>A negative correlation was found between baseline urinary A-megalin levels and change in eGFR (<jats:italic>r<\/jats:italic>\u2009=\u2009\u2212\u20090.458, <jats:italic>P<\/jats:italic>\u2009=\u20090.002). According to Kaplan\u2013Meier survival curves, eGFR decline was associated with the baseline urinary A-megalin quartile (<jats:italic>P<\/jats:italic>\u2009=\u20090.038). In addition, according to the hazard ratios (HRs) for eGFR decline &gt;\u200910\u2009mL\/min\/1.73\u2009m<jats:sup>2<\/jats:sup> calculated using a Cox proportional hazard model, the highest quartile had a significantly higher risk of eGFR decline compared with the lowest quartile (HR 7.243; 95% confidence interval 1.545\u201333.962). Other baseline urinary markers showed no correlation with eGFR decline.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Conclusions<\/jats:title>\n<jats:p>This is the first report demonstrating that prechemotherapy urinary A-megalin levels are correlated with the development of cisplatin-induced nephrotoxicity. This finding has clinical implications for the identification of patients at risk for cisplatin-induced nephrotoxicity and the development of possible prophylactic therapies.<\/jats:p>\n<\/jats:sec>","DOI":"10.1186\/s12885-019-6398-2","type":"journal-article","created":{"date-parts":[[2019,12,2]],"date-time":"2019-12-02T13:03:14Z","timestamp":1575291794000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Correlation of prechemotherapy urinary megalin ectodomain (A-megalin) levels with the development of cisplatin-induced nephrotoxicity: a prospective observational study"],"prefix":"10.1186","volume":"19","author":[{"given":"Satoshi","family":"Shoji","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2750-735X","authenticated-orcid":false,"given":"Michihiro","family":"Hosojima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hideyuki","family":"Kabasawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rie","family":"Kondo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoru","family":"Miura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoshi","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nobumasa","family":"Aoki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryohei","family":"Kaseda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shoji","family":"Kuwahara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naohito","family":"Tanabe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshiaki","family":"Hirayama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ichiei","family":"Narita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshiaki","family":"Kikuchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroshi","family":"Kagamu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akihiko","family":"Saito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,12,2]]},"reference":[{"issue":"10","key":"6398_CR1","doi-asserted-by":"publisher","first-page":"1522","DOI":"10.1016\/S0959-8049(98)00224-X","volume":"34","author":"D Lebwohl","year":"1998","unstructured":"Lebwohl D, Canetta R. Clinical development of platinum complexes in cancer therapy: an historical perspective and an update. Eur J Cancer. 1998;34(10):1522\u201334.","journal-title":"Eur J Cancer"},{"issue":"47","key":"6398_CR2","doi-asserted-by":"publisher","first-page":"7265","DOI":"10.1038\/sj.onc.1206933","volume":"22","author":"ZH Siddik","year":"2003","unstructured":"Siddik ZH. Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene. 2003;22(47):7265\u201379.","journal-title":"Oncogene"},{"issue":"5","key":"6398_CR3","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1016\/S0272-6386(86)80112-3","volume":"8","author":"F Ries","year":"1986","unstructured":"Ries F, Klastersky J. Nephrotoxicity induced by cancer chemotherapy with special emphasis on cisplatin toxicity. Am J Kidney Dis. 1986;8(5):368\u201379.","journal-title":"Am J Kidney Dis"},{"issue":"9","key":"6398_CR4","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1038\/sj.ki.5002786","volume":"73","author":"N Pabla","year":"2008","unstructured":"Pabla N, Dong Z. Cisplatin nephrotoxicity: mechanisms and renoprotective strategies. Kidney Int. 2008;73(9):994\u20131007.","journal-title":"Kidney Int"},{"issue":"1","key":"6398_CR5","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1111\/j.1523-1755.2004.00720.x","volume":"66","author":"T Ludwig","year":"2004","unstructured":"Ludwig T, Riethm\u00fcller C, Gekle M, Schwerdt G, Oberleithner H. Nephrotoxicity of platinum complexes is related to basolateral organic cation transport. Kidney Int. 2004;66(1):196\u2013202.","journal-title":"Kidney Int"},{"issue":"3","key":"6398_CR6","doi-asserted-by":"publisher","first-page":"F505","DOI":"10.1152\/ajprenal.90545.2008","volume":"296","author":"N Pabla","year":"2009","unstructured":"Pabla N, Murphy RF, Liu K, Dong Z. The copper transporter Ctr1 contributes to cisplatin uptake by renal tubular cells during cisplatin nephrotoxicity. Am J Physiol Renal Physiol. 2009;296(3):F505\u201311.","journal-title":"Am J Physiol Renal Physiol"},{"issue":"21","key":"6398_CR7","doi-asserted-by":"publisher","first-page":"9725","DOI":"10.1073\/pnas.91.21.9725","volume":"91","author":"A Saito","year":"1994","unstructured":"Saito A, Pietromonaco S, Loo AK, Farquhar MG. Complete cloning and sequencing of rat gp330\/\"megalin,\" a distinctive member of the low density lipoprotein receptor gene family. Proc Natl Acad Sci U S A. 1994;91(21):9725\u20139.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"4","key":"6398_CR8","first-page":"349","volume":"66","author":"EI Christensen","year":"1995","unstructured":"Christensen EI, Nielsen S, Moestrup SK, Borre C, Maunsbach AB, de Heer E, et al. Segmental distribution of the endocytosis receptor gp330 in renal proximal tubules. Eur J Cell Biol. 1995;66(4):349\u201364.","journal-title":"Eur J Cell Biol"},{"issue":"3","key":"6398_CR9","doi-asserted-by":"publisher","first-page":"333","DOI":"10.3390\/membranes4030333","volume":"4","author":"S De","year":"2014","unstructured":"De S, Kuwahara S, Saito A. The endocytic receptor megalin and its associated proteins in proximal tubule epithelial cells. Membranes (Basel). 2014;4(3):333\u201355.","journal-title":"Membranes (Basel)"},{"issue":"7","key":"6398_CR10","doi-asserted-by":"publisher","first-page":"1996","DOI":"10.1681\/ASN.2015020190","volume":"27","author":"S Kuwahara","year":"2016","unstructured":"Kuwahara S, Hosojima M, Kaneko R, Aoki H, Nakano D, Sasagawa T, et al. Megalin-mediated Tubuloglomerular alterations in high-fat diet-induced kidney disease. J Am Soc Nephrol. 2016;27(7):1996\u20132008.","journal-title":"J Am Soc Nephrol"},{"issue":"3","key":"6398_CR11","doi-asserted-by":"publisher","first-page":"1404","DOI":"10.1172\/JCI118176","volume":"96","author":"SK Moestrup","year":"1995","unstructured":"Moestrup SK, Cui S, Vorum H, Bregeng\u00e5rd C, Bj\u00f8rn SE, Norris K, et al. Evidence that epithelial glycoprotein 330\/megalin mediates uptake of polybasic drugs. J Clin Invest. 1995;96(3):1404\u201313.","journal-title":"J Clin Invest"},{"issue":"6","key":"6398_CR12","doi-asserted-by":"publisher","first-page":"1783","DOI":"10.1681\/ASN.2016060606","volume":"28","author":"Y Hori","year":"2017","unstructured":"Hori Y, Aoki N, Kuwahara S, Hosojima M, Kaseda R, Goto S, et al. Megalin blockade with Cilastatin suppresses drug-induced nephrotoxicity. J Am Soc Nephrol. 2017;28(6):1783\u201391.","journal-title":"J Am Soc Nephrol"},{"issue":"12","key":"6398_CR13","doi-asserted-by":"publisher","first-page":"6319","DOI":"10.1128\/AAC.00254-13","volume":"57","author":"T Suzuki","year":"2013","unstructured":"Suzuki T, Yamaguchi H, Ogura J, Kobayashi M, Yamada T, Iseki K. Megalin contributes to kidney accumulation and nephrotoxicity of colistin. Antimicrob Agents Chemother. 2013;57(12):6319\u201324.","journal-title":"Antimicrob Agents Chemother"},{"issue":"5","key":"6398_CR14","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.2337\/dc11-1684","volume":"35","author":"S Ogasawara","year":"2012","unstructured":"Ogasawara S, Hosojima M, Kaseda R, Kabasawa H, Yamamoto-Kabasawa K, Kurosawa H, et al. Significance of urinary full-length and ectodomain forms of megalin in patients with type 2 diabetes. Diabetes Care. 2012;35(5):1112\u20138.","journal-title":"Diabetes Care"},{"issue":"5","key":"6398_CR15","doi-asserted-by":"publisher","first-page":"1391","DOI":"10.2337\/db16-1031","volume":"66","author":"S De","year":"2017","unstructured":"De S, Kuwahara S, Hosojima M, Ishikawa T, Kaseda R, Sarkar P, et al. Exocytosis-mediated urinary full-length Megalin excretion is linked with the pathogenesis of diabetic nephropathy. Diabetes. 2017;66(5):1391\u2013404.","journal-title":"Diabetes"},{"issue":"4","key":"6398_CR16","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1007\/s00467-016-3535-x","volume":"32","author":"C Suruda","year":"2017","unstructured":"Suruda C, Tsuji S, Yamanouchi S, Kimata T, Huan NT, Kurosawa H, et al. Decreased urinary excretion of the ectodomain form of megalin (A-megalin) in children with OCRL gene mutations. Pediatr Nephrol. 2017;32(4):621\u20135.","journal-title":"Pediatr Nephrol"},{"issue":"33","key":"6398_CR17","doi-asserted-by":"publisher","first-page":"34302","DOI":"10.1074\/jbc.M405608200","volume":"279","author":"Z Zou","year":"2004","unstructured":"Zou Z, Chung B, Nguyen T, Mentone S, Thomson B, Biemesderfer D. Linking receptor-mediated endocytosis and cell signaling: evidence for regulated intramembrane proteolysis of megalin in proximal tubule. J Biol Chem. 2004;279(33):34302\u201310.","journal-title":"J Biol Chem"},{"issue":"10","key":"6398_CR18","doi-asserted-by":"publisher","first-page":"1717","DOI":"10.1038\/sj.ki.5000298","volume":"69","author":"D Biemesderfer","year":"2006","unstructured":"Biemesderfer D. Regulated intramembrane proteolysis of megalin: linking urinary protein and gene regulation in proximal tubule? Kidney Int. 2006;69(10):1717\u201321.","journal-title":"Kidney Int"},{"issue":"1","key":"6398_CR19","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1083\/jcb.201211110","volume":"202","author":"M Shah","year":"2013","unstructured":"Shah M, Baterina OY, Taupin V, Farquhar MG. ARH directs megalin to the endocytic recycling compartment to regulate its proteolysis and gene expression. J Cell Biol. 2013;202(1):113\u201327.","journal-title":"J Cell Biol"},{"issue":"2","key":"6398_CR20","first-page":"98","volume":"20","author":"N Fatima","year":"2010","unstructured":"Fatima N, Niaz K. Maseeh-Uz-Zaman, Kamal S, Hameed a. nephrotoxicity of CDDP assessed estimating glomerular filtration rate with 99mTc-DTPA plasma sample method. J Coll Physicians Surg Pak. 2010;20(2):98\u2013101.","journal-title":"J Coll Physicians Surg Pak"},{"issue":"6","key":"6398_CR21","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1053\/j.ajkd.2008.12.034","volume":"53","author":"S Matsuo","year":"2009","unstructured":"Matsuo S, Imai E, Horio M, Yasuda Y, Tomita K, Nitta K, et al. Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis. 2009;53(6):982\u201392.","journal-title":"Am J Kidney Dis"},{"issue":"12","key":"6398_CR22","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0114400","volume":"9","author":"T Seki","year":"2014","unstructured":"Seki T, Asanuma K, Asao R, Nonaka K, Sasaki Y, Oliva Trejo JA, et al. Significance of urinary full-length megalin in patients with IgA nephropathy. PLoS One. 2014;9(12):e114400.","journal-title":"PLoS One"},{"issue":"6","key":"6398_CR23","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1038\/ki.2012.199","volume":"82","author":"B Humanes","year":"2012","unstructured":"Humanes B, Lazaro A, Camano S, Moreno-Gordaliza E, Lazaro JA, Blanco-Codesido M, et al. Cilastatin protects against cisplatin-induced nephrotoxicity without compromising its anticancer efficiency in rats. Kidney Int. 2012;82(6):652\u201363.","journal-title":"Kidney Int"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-019-6398-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12885-019-6398-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-019-6398-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,30]],"date-time":"2020-11-30T19:35:21Z","timestamp":1606764921000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-019-6398-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12]]},"references-count":23,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["6398"],"URL":"https:\/\/doi.org\/10.1186\/s12885-019-6398-2","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,12]]},"assertion":[{"value":"12 September 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 November 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 December 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was approved by the Institutional Ethics Committee of Niigata University (approval number: 2015\u20131789). The study population included 45 patients who had given written informed consent.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"AS received a research grant from Denka Seiken Co., Ltd. The other authors declare they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1170"}}